TEMERIT

Opinions on drugs - Posted on Oct 04 2006 - Updated on Jan 14 2009

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the new indication

Clinical Benefit

Substantial

The actual benefit is substantial.

Clinical Added Value

moderate

As a result, the Transparency Committee considers that NEBILOX brings about a moderate improvement in actual benefit (IAB III) in the handling of patients aged 70 and over who have mild to moderate stable chronic heart failure, with or without systolic dysfunction.